Teva bails from OncoGenex custirsen deal; paying $27m
Teva will start 2015 by returning the rights to OncoGenex for custirsen, which failed a Phase III metastatic castrate-resistant prostate cancer study this past spring.
Teva will start 2015 by returning the rights to OncoGenex for custirsen, which failed a Phase III metastatic castrate-resistant prostate cancer study this past spring.